Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma. / Hansen, Marcus Høy; Cédile, Oriane; Blum, Mia Koldby; Hansen, Simone Valentin; Ebbesen, Lene Hyldahl; Bentzen, Hans Herluf Nørgaard; Thomassen, Mads; Kruse, Torben A; Kavan, Stephanie; Kjeldsen, Eigil; Kristensen, Thomas Kielsgaard; Haaber, Jacob; Abildgaard, Niels; Nyvold, Charlotte Guldborg.

I: Experimental Hematology, Bind 84, 2020, s. 7-18.e12.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Hansen, MH, Cédile, O, Blum, MK, Hansen, SV, Ebbesen, LH, Bentzen, HHN, Thomassen, M, Kruse, TA, Kavan, S, Kjeldsen, E, Kristensen, TK, Haaber, J, Abildgaard, N & Nyvold, CG 2020, 'Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma', Experimental Hematology, bind 84, s. 7-18.e12. https://doi.org/10.1016/j.exphem.2020.03.001

APA

Hansen, M. H., Cédile, O., Blum, M. K., Hansen, S. V., Ebbesen, L. H., Bentzen, H. H. N., Thomassen, M., Kruse, T. A., Kavan, S., Kjeldsen, E., Kristensen, T. K., Haaber, J., Abildgaard, N., & Nyvold, C. G. (2020). Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma. Experimental Hematology, 84, 7-18.e12. https://doi.org/10.1016/j.exphem.2020.03.001

CBE

Hansen MH, Cédile O, Blum MK, Hansen SV, Ebbesen LH, Bentzen HHN, Thomassen M, Kruse TA, Kavan S, Kjeldsen E, Kristensen TK, Haaber J, Abildgaard N, Nyvold CG. 2020. Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma. Experimental Hematology. 84:7-18.e12. https://doi.org/10.1016/j.exphem.2020.03.001

MLA

Vancouver

Author

Hansen, Marcus Høy ; Cédile, Oriane ; Blum, Mia Koldby ; Hansen, Simone Valentin ; Ebbesen, Lene Hyldahl ; Bentzen, Hans Herluf Nørgaard ; Thomassen, Mads ; Kruse, Torben A ; Kavan, Stephanie ; Kjeldsen, Eigil ; Kristensen, Thomas Kielsgaard ; Haaber, Jacob ; Abildgaard, Niels ; Nyvold, Charlotte Guldborg. / Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma. I: Experimental Hematology. 2020 ; Bind 84. s. 7-18.e12.

Bibtex

@article{8cfb1ab7da4f486a96b1a2d25d100ef5,
title = "Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma",
abstract = "Mantle Cell lymphoma (MCL) is a tumor with poor prognosis. A few studies have examined the molecular landscape by next generation sequencing and provided valuable insights into recurrent lesions driving this heterogeneous cancer. However, none have attempted to cross-link the individual genomic and transcriptomic profile in sorted MCL cells in order to perform individual molecular characterizations of the lymphomas. Such approaches are relevant as MCL is heterogenous by nature, and thorough molecular diagnostics may potentially benefit the patient with more focused treatment options. Here, we use sorted lymphoma cells from four patients at diagnosis and relapse by intersecting the coding DNA and mRNA. In spite of only few patients included, this method enabled us to pinpoint a specific set of expressed somatic mutations and to present an overall expression profile different from the normal B cell counterparts, and to track molecular aberrations from diagnosis to relapse. Changes of single nucleotide coding variants, subtle clonal changes in large copy number alterations, subclonal involvement and changes in expression levels in the clinical course provided detailed information on each of the individual malignancies. In addition to mutations in known genes (e.g. TP53, CCND1, NOTCH1, ATM), we identified others, not linked to MCL, such as a nonsense mutation in SPEN and MYD88 missense mutation in one patient, which along with copy number alterations showed molecular resemblance towards splenic marginal zone lymphoma. The detailed exonic and transcriptomic portrait of the individual MCL patients by the methodology presented here could help in diagnostics, surveillance and a potentially more precise usage of therapeutic drugs by efficient screen of biomarkers.",
author = "Hansen, {Marcus H{\o}y} and Oriane C{\'e}dile and Blum, {Mia Koldby} and Hansen, {Simone Valentin} and Ebbesen, {Lene Hyldahl} and Bentzen, {Hans Herluf N{\o}rgaard} and Mads Thomassen and Kruse, {Torben A} and Stephanie Kavan and Eigil Kjeldsen and Kristensen, {Thomas Kielsgaard} and Jacob Haaber and Niels Abildgaard and Nyvold, {Charlotte Guldborg}",
note = "Copyright {\textcopyright} 2020. Published by Elsevier Inc.",
year = "2020",
doi = "10.1016/j.exphem.2020.03.001",
language = "English",
volume = "84",
pages = "7--18.e12",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma

AU - Hansen, Marcus Høy

AU - Cédile, Oriane

AU - Blum, Mia Koldby

AU - Hansen, Simone Valentin

AU - Ebbesen, Lene Hyldahl

AU - Bentzen, Hans Herluf Nørgaard

AU - Thomassen, Mads

AU - Kruse, Torben A

AU - Kavan, Stephanie

AU - Kjeldsen, Eigil

AU - Kristensen, Thomas Kielsgaard

AU - Haaber, Jacob

AU - Abildgaard, Niels

AU - Nyvold, Charlotte Guldborg

N1 - Copyright © 2020. Published by Elsevier Inc.

PY - 2020

Y1 - 2020

N2 - Mantle Cell lymphoma (MCL) is a tumor with poor prognosis. A few studies have examined the molecular landscape by next generation sequencing and provided valuable insights into recurrent lesions driving this heterogeneous cancer. However, none have attempted to cross-link the individual genomic and transcriptomic profile in sorted MCL cells in order to perform individual molecular characterizations of the lymphomas. Such approaches are relevant as MCL is heterogenous by nature, and thorough molecular diagnostics may potentially benefit the patient with more focused treatment options. Here, we use sorted lymphoma cells from four patients at diagnosis and relapse by intersecting the coding DNA and mRNA. In spite of only few patients included, this method enabled us to pinpoint a specific set of expressed somatic mutations and to present an overall expression profile different from the normal B cell counterparts, and to track molecular aberrations from diagnosis to relapse. Changes of single nucleotide coding variants, subtle clonal changes in large copy number alterations, subclonal involvement and changes in expression levels in the clinical course provided detailed information on each of the individual malignancies. In addition to mutations in known genes (e.g. TP53, CCND1, NOTCH1, ATM), we identified others, not linked to MCL, such as a nonsense mutation in SPEN and MYD88 missense mutation in one patient, which along with copy number alterations showed molecular resemblance towards splenic marginal zone lymphoma. The detailed exonic and transcriptomic portrait of the individual MCL patients by the methodology presented here could help in diagnostics, surveillance and a potentially more precise usage of therapeutic drugs by efficient screen of biomarkers.

AB - Mantle Cell lymphoma (MCL) is a tumor with poor prognosis. A few studies have examined the molecular landscape by next generation sequencing and provided valuable insights into recurrent lesions driving this heterogeneous cancer. However, none have attempted to cross-link the individual genomic and transcriptomic profile in sorted MCL cells in order to perform individual molecular characterizations of the lymphomas. Such approaches are relevant as MCL is heterogenous by nature, and thorough molecular diagnostics may potentially benefit the patient with more focused treatment options. Here, we use sorted lymphoma cells from four patients at diagnosis and relapse by intersecting the coding DNA and mRNA. In spite of only few patients included, this method enabled us to pinpoint a specific set of expressed somatic mutations and to present an overall expression profile different from the normal B cell counterparts, and to track molecular aberrations from diagnosis to relapse. Changes of single nucleotide coding variants, subtle clonal changes in large copy number alterations, subclonal involvement and changes in expression levels in the clinical course provided detailed information on each of the individual malignancies. In addition to mutations in known genes (e.g. TP53, CCND1, NOTCH1, ATM), we identified others, not linked to MCL, such as a nonsense mutation in SPEN and MYD88 missense mutation in one patient, which along with copy number alterations showed molecular resemblance towards splenic marginal zone lymphoma. The detailed exonic and transcriptomic portrait of the individual MCL patients by the methodology presented here could help in diagnostics, surveillance and a potentially more precise usage of therapeutic drugs by efficient screen of biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85084531465&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2020.03.001

DO - 10.1016/j.exphem.2020.03.001

M3 - Journal article

C2 - 32173361

VL - 84

SP - 7-18.e12

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

ER -